In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research ...

Revolution Medicines Inc's commitment to precision oncology positions it at the forefront of targeted cancer therapies.

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a ...

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports. They currently ...

Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...

On Friday, Revolution Medicines Inc (RVMD) stock saw a modest uptick, ending the day at $60.44 which represents a slight increase of $1.34 or 2.27% from the prior close of $59.1. The stock opened at ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.66% ...